Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia~* Measurable disease~* Have received at least one prior therapy for WM therapies~* Disease free of prior malignancies~* Able to adhere to study visit schedule and other protocol requirement~Exclusion Criteria:~* Pregnant or breastfeeding~* Any other serious medical condition~* Concurrent use of other anti-cancer agents or treatments~* Prior exposure to PCI-32765~* Known CNS lymphoma~* Significant cardiovascular disease~* Any disease affecting gastrointestinal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): PCI-32765; ibrutinib

Based on this trial design, predict the completion outcome and termination type (if applicable).